Research programme: monoclonal antibody therapeutics - Allakos
Alternative Names: AK003Latest Information Update: 28 Aug 2020
At a glance
- Originator Allakos
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 04 Jul 2016 Early research in Cancer in USA (Parenteral) before July 2016 (Allakos Pipeline, July 2016)